文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > 临床医学 > CD20-specific adoptive immunotherapy for lymphoma
侵权投诉

CD20-specific adoptive immunotherapy for lymphoma

BLOOD,26APRIL2012 VOLUME119,NUMBER17

wasthemosteffectiveintermsofproliferationandcytokineproduction.23Wethereforeselectedthisconstructforclinicaltestingandreportheretheresultsofasmallpilottrialtestingthis“third-generation”CAR.

Methods

Clinicaltrialprotocol

ThisclinicalprotocolwasapprovedbytheFredHutchinsonCancerResearchCenterInstitutionalReviewBoard,UniversityofWashingtonInstitutionalBiosafetyCommittee,andtheNationalInstitutesofHealthRecombinantDNAAdvisoryCommittee,andissupportedbytheUnitedStatesFoodandDrugAdministration(BB-IND13390).Thisstudyisregisteredatdoc.guandang.net rmeddiagnosisofCD20 MCLorindolentB-celllymphoma,hadrelapsedorrefractorydiseaseafteratleastonepriorchemotherapy,weredeemednottobecandidatesfor(orrefused)SCT,andhadserologicevidenceofpriorEpstein-Barrvirus(EBV)exposure(becausetheTM-LCLcelllineusedinT-cellcultureisEBV-transformed).Patientswereexcludediftheyhadreceived udarabineorcladribinewithin2yearsbeforeapheresis(thesedrugscauseaprotractedlymphopeniathatcouldpotentiallyimpairthenumberorfunctionofTcellscollectedduringapheresis),anti-CD20Absorchemotherapywithin4weeksofT-cellinfusions;hadlymphnodeslargerthan5cmormorethan5000circulatinglymphomacellsintheperipheralbloodatthetimeofT-cellinfusions,previousallogeneicSCT,orhumananti–mouseAbseropositivity.

Patientsunderwentapheresistocollectperipheralbloodmononuclearcells(PBMCs)andcouldthenreceivecytoreductivechemotherapyfordiseasecontrolordebulkingduringthe2-the3-monthperiodofT-cellexpansion,atthediscretionofthereferringphysician.ReleasecriteriaforexvivoexpandedTcellswereasfollows:sterilitybyUnitedStatesPharmacopeia,fungal,andmycoplasmatesting,negativeGramstain,endotoxinlessthan5U/kg,morethan70%viabilitybyTrypanBlueexclusion,CD3 andTCR by owcytometry,IL-2–dependentgrowth,andCD20-speci ccytotoxicityofmorethan20%lysisat100:1E:Tratio.Patientssubsequentlyreceivedcyclophosphamide(CY)1000mg/m2intra-venouslytoachievelymphodepletion2daysbeforestartingaseriesof3infusionsofautologousCD20-speci cTcells2to5daysapartinescalatingdoses(108,109,and3.3 109cells/m2),followedby14daysofsubcutaneouslow-dose(250000IU/m2)IL-2injectionstwicedaily.Anexcisionalbiopsyofapalpablelymphnodeandabonemarrowbiopsywereperformedoneachpatient24to48hoursafterthe nalT-cellinfusion.Anotherbonemarrowbiopsyatthe1-monthtimepointwasoptional.Patientsunderwentclinicalfollow-uptoevaluatetoxicitiesrelatedtotherapy,whichwereassessedaccordingtoNationalInstitutesofHealthCommonTerminologyCriteriaforAdverseEventsVersion3.0(doc.guandang.net).ClinicalresponseswereassessedaccordingtoInterna-tionalWorkingGroupcriteria.25

Modi cationandexpansionofCD20-speci cTcells

CD20-speci cTcellsweregeneratedaspreviouslydescribed.15,23PatientPBMCswereactivatedwithOKT3andIL-2,and4dayslaterwereelec-troporatedwiththeL29.19.1plasmid,23whichencodesaLeu16(murineanti–humanCD20)scFvfusedtoahumanIgG1CH2-CH3hinge,CD4trans-membrane,intracellularCD28(withmutateddileucinemotif)26andCD137(4-1BB)costimulatorydomains,andCD3 ,underthecontroloftheCMVimmediate-earlypromoter,hereafterdenotedasthe CD20-28-BB- CAR,aswellasaneomycinresistancegeneunderthecontrolofanSV40promoter.Transfectedcellswererestimulatedin12-to15-daycyclesusingarapidexpansionprotocol15,27andselectedwithG418duringthe rst,third,andfourthstimulationcycles.G418-resistantcellsweretransferredfrom askstoculturebagsuntilthetargetcelldosewasreached.

CD20-CARTHERAPYFORNHL3941

Insomeinstances,batchesofcellswerecryopreservedduringexpansionandthawedbeforeinfusion.Cytotoxicityassays

Standard5-hourchromiumreleaseassayswereperformedaspreviouslydescribed,15usingthefollowingtargets:EL4(negativecontrol),EL4-CD20(EL4cellstransfectedtoexpressCD20),Granta(CD20 MCLline),andDaudi(CD20 Burkittlymphomacellline).Flowcytometry

ImmunophenotypesofexvivoexpandedTcellswereassessedbythawingandwashingpre-infusionTcells,andincubated30minutesat4°Cwiththefollowingantibodies,allfromBDBiosciences:anti-CD3–PE,anti-CD4–FITC,anti-CD8–FITC,anti-CD25–PE,anti-CD27–FITC,anti-CD28–FITC,anti-CD44–PE,anti-CD45RA–FITC,anti-CD45RO–FITC,anti-CD56–PE,anti-CD57–FITC,anti-CD62–PE,anti-CD183(CXCR3)–PE,andanti-CD197(CCR7)–FITC.CellsurfaceIL-15andIL-15R weremeasuredbylabelingthawed,washedpatientPBMCsfrombaselineandserialpost-CYtimepointswitheitheranti-CD3–PEoranti-CD14–PE(BDBiosciences)andeitheranti–IL-15–FITC(R&DSystems)oranti–IL-15R –FITC(eBioscience)andpropidiumiodide(BDBiosciences).CellswerewashedwithPBSplus0.5%FCS,andapproximately20000eventswereacquiredonaFACSCaliburmachine(BDBiosciences).DatawereanalyzedusingFlowJoVersion7.6.1software(TreeStar).CARexpressionwasassessedbyFACSusingFITC-conjugatedgoatanti–mouseIgGF(ab )2orPE-conjugatedgoatanti–humanIgGFc(JacksonImmunoResearchLaboratories)aspreviouslydescribed.15,23Lymphocytesubsetsinseriallycollectedperipheralbloodsampleswereanalyzedusingmultiparameter owcytometryaspreviouslydescribed.15

QuantitativePCRtodetectmodi edTcells

PatientPBMCscollectedatbaselineandatserialtimepointsafterT-cellinfusionswerecollectedandseparatedbyFicollcentrifugationandthencryopreserved.BatchedcellswerethawedandgenomicDNAwashar-vestedusingaDNeasyBloodandTissueKit(QIAGEN).TheCARtransgenewasdetectedbyperformingquantitativePCRaspreviouslydescribed,15usingeitheraprimeramplifyinga111-bpfragmentspanningthejunctionoftheCD4transmembraneregionandadjacentCD28domain(forwardprimer:5 -TGGGCTAGGCATCTTCTTCA-3 ,reverseprimer:5 -GCATAGGGCTGGTAATGCTT-3 ,probe:5 -FAM-CACAGTGACTA-CATGAACATGAC-TAMRA-3 ),oraprimeramplifyinga113-bpfrag-mentspanningthejunctionofCD137domainandadjacentCD3 chain(forwardprimer:5 -GAAGAAGGAGGATGTGAACT-3 ,reverseprimer:5 -TCCTCTCTTCGTCCTAGATT-3 ,probe:5 -FAM-AGGGCCAGAAC-CAGCTCTATAA-TAMRA-3 ).Quantitativereal-timePCRwasperformedintriplicateusingTaqManUniversalPCRMasterMix(AppliedBiosys-tems),ina7900HTFastReal-TimePCRSystem(AppliedBiosystems).CopynumberspermicrogramofgenomicDNA,generatedfromastandardcurveof10-foldserialdilutionsofpuri edplasmid,wereusedtocalculatethepercentageofCAR cellsamongPBMCs,assuming1copy/cell,28basedon:1 ggenomicDNA/6.7pgDNApercell 1.49 105cells.Immuneresponseassays

Twohumoralimmuneresponseassayswereperformed:anELISAassaydetectingAbagainsttheLeu16murineanti-CD20AbandaFACSassaydetectingAbagainstHEK-293cellstransfectedwiththeL29.19.1vector.AcellularimmuneresponseassaywasperformedtodetectTcellsrespondingtostimulationwithcellsexpressingthetransgeneproducts.DetailsofimmuneresponseassaysareprovidedinsupplementalMethods(availableontheBloodWebsite;seetheSupplementalMaterialslinkatthetopoftheonlinearticle).Telomereanalysis

PatientPBMCsobtainedatapheresiswerethawed,washed,andseparatedoveraFicollgradient,andpositivelyCD3-selectedbyMACS(Miltenyi

上一页第2页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email